Clinical TrialJul 22, 2026, 04:37 PM
Alzamend Neuro AL001 Shows Superior Brain Penetration; ALZN002 Trial Delayed
AI Summary
Alzamend Neuro provided updates on its clinical pipeline, reporting positive Phase II "Lithium in Brain" study results for AL001, demonstrating superior brain penetration and faster uptake compared to standard lithium carbonate. The company initiated a Phase II trial for AL001 in Bipolar Disorder, with further trials planned for MDD, PTSD, and Alzheimer's. However, the Phase I/IIA clinical trial for ALZN002 has been delayed, with a restart now expected in Q1 2027 due to a change in contract research organization.
Key Highlights
- AL001 Phase II "Lithium in Brain" study confirmed bioequivalence to standard lithium carbonate.
- AL001 showed numerically higher lithium concentrations in all measured brain regions.
- AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonate.
- AL001 exhibited a potentially distinct brain profile and preserved glutamate balance.
- Initiated AL001 Phase II clinical trial for Bipolar Disorder, topline data expected Q4 2026.
- AL001 trials for MDD and PTSD expected Q4 2026, Alzheimer's in Q1 2027.
- ALZN002 Phase I/IIA clinical trial delayed, restart expected Q1 2027 due to CRO change.
Price Impact
More from ALZN